Name: Traveler's Diarrhea Market Size, Share, Industry, Forecast and outlook (2023-2030)
Brand: DataM Intelligence
SKU: PH3492
Price: 4350 USD
Availability: InStock

Traveler's Diarrhea Market Size Share Trends Growth & Forecast 2023-2030

Traveler's Diarrhea Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Global Traveler&#39;s Diarrhea Market is segmented By Drug Class&nbsp;(Antibiotics, Oral Rehydration Therapy (ORS),&nbsp;Antidiarrheal Agents, Vaccines/Prophylactics, Others), By Pathogen&nbsp;(Bacteria, Viruses, Protozoa), By Age Group&nbsp;(Adults, Children), By Distribution Channel&nbsp;(Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region&nbsp;(North America, Europe, South America, Asia Pacific, Middle East,&nbsp;and Africa)&nbsp;&ndash; Share, Size, Outlook, and Opportunity Analysis, 2022-2029</h2>

&nbsp;

<h2>Market Overview</h2>

<blockquote>
The global traveler&#39;s diarrhea market size was valued US$ XX billion in 2022&nbsp;and is estimated to reach US$ XX billion by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).&nbsp;
</blockquote>

Traveler&#39;s diarrhea is a digestive tract disorder characterized by an intestinal infection that occurs when a person consumes contaminated food and water.

<h2>Market Dynamics</h2>

The traveler&#39;s diarrhea market growth is driven due to the surge in the number of travelers, rising awareness among travelers, development of novel treatments is anticipated to drive the traveler&rsquo;s diarrhea market.

Surge in the number of travelers, is expected to drive the global traveler&rsquo;s diarrhea market growth

The risk of acquiring traveler&rsquo;s diarrhea is high in developing countries like Africa, the Middle East, Asia, and Latin America. An increase in the number of travelers to developing countries in these regions is driving the number of traveler&rsquo;s diarrhea patients. For instance, according to The World Tourism Organization (UNWTO), in 2018, estimated international tourist arrivals (overnight visitors) increased 6% to 1.4 billion across the world. According to the world atlas, Southeast Asia receives the highest number of travelers, and an estimated 55.6 million people visited China, Thailand received 24.8 million visitors, South Korea welcomed 14.2 million, Japan 13.4 million, and Indonesia received 10.4 million visitors annually. As per the Center for Disease Control and Prevention (CDC), in 2016, more than 6 million international travelers visited Brazil. The rise in the number of travelers is boosting travel expenditure. For instance, according to The U.S. Travel Association, in the U.S., an estimated US$ 1.1 trillion was spent by domestic and international inbound travelers.

Growing awareness among travelers, is expected to drive the global traveler&rsquo;s diarrhea market growth

The rise in awareness among travelers is anticipated to drive the global traveler&rsquo;s diarrhea market. For instance, pre-travel counseling is essential due to a rise in the number of travelers and knowledge related to traveler&rsquo;s medicine. The goal of pre-travel consultation is to improve the understanding of travelers about travel-related health hazards and diseases.

Growing self-medication by using OTC products coupled with antibiotic resistance is likely to hamper the market growth 

An increase in the use of over-the-counter medication to treat traveler&rsquo;s diarrhea is anticipated to hamper the market. For instance, according to an article published in The Journal of Life and Environmental Sciences, the study conducted during 2013-2014 in China Mainland, the estimated rate of antibiotic misuse was 35.12%.

The rise in the use of antibiotics increases the risk of antibiotic resistance. Therefore, as per WHO guidelines, antibiotics are restricted to cholera with severe dehydration and bloody diarrhea.

<h2>&nbsp;</h2>

COVID-19 Impact Analysis

Following the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries globally, and the World Health Organization has declared it a public health emergency. According to the World Health Organization&rsquo;s report, the coronavirus (COVID-19) manifestation has resulted in more than 52.7 million infected individuals worldwide as of November 13, 2020.

COVID-19 has affected every market globally and has also impacted the global traveler&rsquo;s diarrhea market in the following ways; by directly affecting production and demand, creating disruptions in distribution channels, and its financial impact on firms and financial markets.

Furthermore, players operating in the global traveler&rsquo;s diarrhea market face significant challenges on various fronts due to the COVID-19 pandemic. The significant challenges include the supply of raw materials for manufacturing drug formulations due to irregularities in the transportation facility. Moreover, distributors of products are experiencing irregular demand for products from the retailers due to the increasing patient population suffering from COVID-19 and other life-threatening disorders.

<h2>Segment Analysis</h2>

The antibiotics segment is expected to hold largest share in this market segment

Antibiotics used to treat and manage traveler&rsquo;s diarrhea have evolved rapidly in the past 50 years due to various factors, including drug resistance, costs, and side effects. However, with consistent developments in research, new and improved treatments for traveler&rsquo;s diarrhea are entering the traveler&rsquo;s diarrhea market.

The Food and Drug Administration (FDA) has approved several new treatments and drugs in recent years. For instance, Aemcolo, an oral antibacterial rifamycin, was approved by the FDA in November 2018 to treat traveler&rsquo;s diarrhea caused by E. coli. Clinical studies have revealed that rifamycin has greater efficiency in reducing diarrhea symptoms than placebo. Antibiotics are primarily recommended to treat severe traveler&rsquo;s diarrhea. Despite a few side effects, antibiotics are likely to stay ahead within the drug class segment. The management and treatment of traveler&rsquo;s diarrhea are expected to evolve, owing to the formulation of different guidelines laid down by regulatory bodies worldwide. As per the new guidelines, antibiotics for mild traveler&rsquo;s diarrhea are not recommended, as they have been linked to adverse events.

The bacteria segment is expected to hold largest share in this market segment

According to CDC Center for Disease Control and Prevention, bacteria cause nearly 80% of the cases. E. coli and Salmonella Spp are the two major bacteria types responsible for traveler&rsquo;s diarrhea. According to the British Medical Journal, the prevalence of traveler&rsquo;s diarrhea is higher among travelers visiting regions in South Asia and Southeast Asia.

The adults traveler&rsquo;s diarrhea segment is expected to hold largest share in this market segment

According to the American family physician journal, Traveler&rsquo;s diarrhea is more common in young children than in adults, and they have a higher risk of dehydration and severe illness. The use of oral rehydration solutions is essential, and parents should include prepackaged packets (to be mixed with safe water) in their travel kits.

The retail pharmacies segment is expected to hold largest share in this market segment

A retail pharmacy refers to an independent pharmacy with a state license to dispense medications to the general public. People are increasingly adopting retail pharmacies as a one-stop shop to buy medicines. They are highly preferred by people who cannot reach hospitals for a check-up regularly and need medicine for quick treatment. The better outreach of retail pharmacies makes them a highly profitable segment and the most established one across several countries.

<h2>Geographical Analysis</h2>

North America region holds the largest market share of global traveler&rsquo;s diarrhea market 

The North American region holds the largest share of the market due to the increasing burden of traveler&rsquo;s diarrhea and the strong presence of manufacturers in this region. The rising awareness, along with the easy availability of over-the-counter medications, is likely to favor the growth of the traveler&rsquo;s diarrhea market in North America. For instance, according to The U.S. Travel Association, in the U.S., an estimated US$ 1.1 trillion was spent by domestic and international inbound travelers. In April 2019, Health Canada approved Travelan in Canada.

<h2>Competitive Landscape</h2>

The global traveler&#39;s diarrhea market is highly competitive with presence of global companies.&nbsp; Some of the key players which are contributing to the growth of the market include Bausch Health Companies Inc. (Salix Pharmaceuticals), Bristol-Myers Squibb Company, Cosmo Pharmaceuticals NV, Immuron Limited, Johnson &amp; Johnson, Pfizer Inc., Procter &amp; Gamble, Sanofi SA, Valneva Canada Inc, Sun Pharmaceutical Industries Ltd. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, In November 2018, COSMO PHARMACEUTICALS received U.S. Food and Drug Administration approval for Aemcolo for the treatment of traveler&rsquo;s diarrhea.

<h2>Key Companies to Watch</h2>

Bausch Health Companies Inc

Company Overview: Bausch Health Companies Inc. is a multinational specialty pharmaceutical company based in Laval, Quebec, Canada. Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies committed to the prevention and treatment of gastrointestinal (GI) diseases and disorders. It manufactures and markets a broad range of branded and generic pharmaceuticals, over-the-counter (OTC) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetic devices) directly or indirectly in more than 90 countries and regions, including the United States, Canada, Europe, the Middle East, Africa, Asia Pacific and Latin America. Each day, its products are used by up to 150 million people around the world.

Product portfolio: The Company&rsquo;s portfolio comprised of include have a diversified portfolio of products, with a core focus in the following areas Eye health (Bausch + Lomb), Gastrointestinal Diseases (Salix Pharmaceuticals), Dermatology (Ortho Dermatologics).

Key Developments: In October 2019, Bausch Health Companies Inc. announced the receipt of the U.S. patent and Trademark patent covering use of XIFAXAN. This enabled the company to strengthen the intellectual property of XIFAXAN.

Why Purchase the Report?

<ul>
	<li>Visualize the composition of the traveler&#39;s diarrhea market segmentation by drug class, pathogen, age group, distribution channel and region highlighting the key commercial assets and players.</li>
	<li>Identify commercial opportunities in traveler&#39;s diarrhea market by analyzing trends and co-development deals.</li>
	<li>Excel data sheet with thousands of data points of traveler&#39;s diarrhea market - level 4/5 segmentation.</li>
	<li>PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.</li>
	<li>Product mapping in excel for the key product of all major market players</li>
</ul>

The global traveler&#39;s diarrhea market report would provide an access to an approx. 69 market data table, 63 figures and 200 pages.&nbsp; 

Target Audience

<ul>
	<li>Service Providers/ Buyers</li>
	<li>Industry Investors/Investment Bankers</li>
	<li>Education &amp; Research Institutes</li>
	<li>Research Professionals</li>
	<li>Emerging Companies</li>
	<li>Manufacturers</li>
</ul>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Contents</h2>

<ol>
	<li>
	<h3>Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3>Market Definition and Overview</h3>
	</li>
	<li>
	<h3>Executive Summary</h3>

	<ol>
		<li>Market Snippet by Drug Class</li>
		<li>Market Snippet by Pathogen</li>
		<li>Market Snippet by Age group</li>
		<li>Market Snippet by Distribution Channel</li>
		<li>Market Snippet by Region</li>
	</ol>
	</li>
	<li>
	<h3>Market Dynamics</h3>

	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Surge in the number of travelers</li>
				<li>Growing awareness among travelers</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>Growing self-medication by using OTC products coupled with antibiotic resistance</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Industry Analysis</h3>

	<ol>
		<li>Porter&#39;s Five Forces Analysis</li>
		<li>PEST Analysis</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Reimbursement Analysis</li>
		<li>Unmet Needs</li>
	</ol>
	</li>
	<li>
	<h3>COVID-19 Analysis</h3>

	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3>By Drug Class</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Attractiveness Index, By Drug Class</li>
		</ol>
		</li>
		<li>&nbsp;Antibiotics*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
			<li>Azithromycin,</li>
			<li>Ciprofloxacin</li>
			<li>Quinolones</li>
			<li>Rifaximi</li>
		</ol>
		</li>
		<li>Oral Rehydration Therapy (ORS),</li>
		<li>Antidiarrheal Agents</li>
		<li>Vaccines/Prophylactics</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3>By Pathogen</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Segment</li>
			<li>Market Attractiveness Index, By Pathogen Segment</li>
		</ol>
		</li>
		<li>&nbsp;Bacteria*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
			<li>E. Coli</li>
			<li>Salmonella Spp</li>
			<li>Others</li>
		</ol>
		</li>
		<li>Viruses</li>
		<li>Protozoa</li>
	</ol>
	</li>
	<li>
	<h3>By Age Group</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group Segment</li>
			<li>Market Attractiveness Index, By Age Group Segment</li>
		</ol>
		</li>
		<li>&nbsp;Adults*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Children</li>
	</ol>
	</li>
	<li>
	<h3>By Distribution Channel</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment</li>
			<li>Market Attractiveness Index, By Distribution Channel Segment</li>
		</ol>
		</li>
		<li>&nbsp;Retail Pharmacies*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Hospital Pharmacies</li>
		<li>Online Pharmacies</li>
	</ol>
	</li>
	<li>
	<h3>By Region</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug-Class</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug-Class</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug-Class</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug-Class</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug-Class</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Competitive Landscape</h3>

	<ol>
		<li>Key Developments and Strategies</li>
		<li>Company Share Analysis</li>
		<li>Product Benchmarking</li>
		<li>Key Companies to Watch</li>
		<li>Company with disruptive technology</li>
		<li>Start Up Companies</li>
	</ol>
	</li>
	<li>
	<h3>Company Profiles</h3>

	<ol>
		<li>Bausch Health Companies Inc (Salix Pharmaceuticals) *
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview</li>
		</ol>
		</li>
		<li>Bristol-Myers Squibb Company</li>
		<li>Cosmo Pharmaceuticals NV</li>
		<li>Immuron Limited</li>
		<li>Johnson &amp; Johnson</li>
		<li>Pfizer Inc</li>
		<li>Procter &amp; Gamble</li>
		<li>Sanofi SA</li>
		<li>Valneva Canada Inc</li>
		<li>Sun Pharmaceutical Industries Ltd</li>
		<li>Shanghai Yingrui Biopharma Co., Ltd</li>
		<li>Shijiazhuang Gantuo Biotechnology Co., Ltd</li>
		<li>PI &amp; PI BIOTECH INC(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>
	<h3>DataM Intelligence</h3>

	<ol>
		<li>Appendix</li>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

List of Tables

Table 1 Global Traveler&#39;s Diarrhea Market Value, By Drug Class, 2021,2025 &amp; 2029($ Million)

Table 2 Global Traveler&#39;s Diarrhea Market Value, By Pathogen, 2021,2025 &amp; 2029($ Million)

Table 3 Global Traveler&#39;s Diarrhea Market Value, By Age Group, 2021,2025 &amp; 2029($ Million)

Table 4 Global Traveler&#39;s Diarrhea Market Value, By Distribution Channel, 2021,2025 &amp; 2029($ Million)

Table 5 Global Traveler&#39;s Diarrhea Market Value, By Region, 2021,2025 &amp; 2029($ Million)

Table 6 Global Traveler&#39;s Diarrhea Market Value, By Drug Class, 2021,2025 &amp; 2029($ Million)

Table 7 Global Traveler&#39;s Diarrhea Market Value, By Drug Class, 2018-2029($ Million)

Table 8&nbsp;&nbsp;&nbsp;&nbsp; Global Traveler&#39;s Diarrhea Market Value, By Pathogen, 2021,2025 &amp; 2029($ Million)

Table 9 Global Traveler&#39;s Diarrhea Market Value, By Pathogen, 2018-2029($ Million)

Table 10&nbsp;&nbsp; Global Traveler&#39;s Diarrhea Market Value, By Age Group, 2021,2025 &amp; 2029($ Million)

Table 11&nbsp;&nbsp;&nbsp; Global Traveler&#39;s Diarrhea Market Value, By Age Group, 2018-2029($ Million)

Table 12&nbsp;&nbsp; Global Traveler&#39;s Diarrhea Market Value, By Distribution Channel, 2021,2025 &amp; 2029($ Million)

Table 13&nbsp;&nbsp; Global Traveler&#39;s Diarrhea Market Value, By Distribution Channel, 2018-2029($ Million)

Table 14&nbsp;&nbsp; Global Traveler&#39;s Diarrhea Market Value, By Region, 2021,2025 &amp; 2029($ Million)

Table 15&nbsp;&nbsp; Global Traveler&#39;s Diarrhea Market Value, By Region, 2018-2029($ Million)

Table 16&nbsp;&nbsp; North America Traveler&#39;s Diarrhea Market Value, By Drug Class, 2018-2029($ Million)

Table 17&nbsp;&nbsp;&nbsp; North America Traveler&#39;s Diarrhea Market Value, By Pathogen, 2018-2029($ Million)

Table 18&nbsp;&nbsp; North America Traveler&#39;s Diarrhea Market Value, By Age Group, 2018-2029($ Million)

Table 19&nbsp;&nbsp; North America Traveler&#39;s Diarrhea Market Value, By Distribution Channel, 2018-2029($ Million)

Table 20&nbsp;&nbsp; North America Traveler&#39;s Diarrhea Market Value, By Country, 2018-2029($ Million)

Table 21&nbsp;&nbsp; South America Traveler&#39;s Diarrhea Market Value, By Drug Class, 2018-2029($ Million)

Table 22&nbsp;&nbsp; South America Traveler&#39;s Diarrhea Market Value, By Pathogen, 2018-2029($ Million)

Table 23&nbsp;&nbsp; South America Traveler&#39;s Diarrhea Market Value, By Age Group, 2018-2029($ Million)

Table 24&nbsp;&nbsp; South America Traveler&#39;s Diarrhea Market Value, By Distribution Channel, 2018-2029($ Million)

Table 25&nbsp;&nbsp; South America Traveler&#39;s Diarrhea Market Value, By Country, 2018-2029($ Million)

Table 26&nbsp;&nbsp; Europe Traveler&#39;s Diarrhea Market Value, By Drug Class, 2018-2029($ Million)

Table 27&nbsp;&nbsp; Europe Traveler&#39;s Diarrhea Market Value, By Pathogen, 2018-2029($ Million)

Table 28&nbsp;&nbsp; Europe Traveler&#39;s Diarrhea Market Value, By Age Group, 2018-2029($ Million)

Table 29&nbsp;&nbsp; Europe Traveler&#39;s Diarrhea Market Value, By Distribution Channel, 2018-2029($ Million)

Table 30&nbsp;&nbsp; Europe Traveler&#39;s Diarrhea Market Value, By Country, 2018-2029($ Million)

Table 31&nbsp;&nbsp; Asia-Pacific Traveler&#39;s Diarrhea Market Value, By Drug Class, 2018-2029($ Million)

Table 32&nbsp;&nbsp; Asia-Pacific Traveler&#39;s Diarrhea Market Value, By Pathogen, 2018-2029($ Million)

Table 33&nbsp;&nbsp; Asia-Pacific Traveler&#39;s Diarrhea Market Value, By Age Group, 2018-2029($ Million)

Table 34&nbsp;&nbsp; Asia-Pacific Traveler&#39;s Diarrhea Market Value, By Distribution Channel, 2018-2029($ Million)

Table 35&nbsp;&nbsp; Asia-Pacific Traveler&#39;s Diarrhea Market Value, By Country, 2018-2029($ Million)

Table 36&nbsp;&nbsp; Middle East &amp; Africa Traveler&#39;s Diarrhea Market Value, By Drug Class, 2018-2029($ Million)

Table 37&nbsp;&nbsp; Middle East &amp; Africa Traveler&#39;s Diarrhea Market Value, By Pathogen, 2018-2029($ Million)

Table 38&nbsp;&nbsp; Middle East &amp; Africa Traveler&#39;s Diarrhea Market Value, By Age Group, 2018-2029($ Million)

Table 39&nbsp;&nbsp; Middle East &amp; Africa Traveler&#39;s Diarrhea Market Value, By Distribution Channel, 2018-2029($ Million)

Table 40&nbsp;&nbsp; Bausch Health Companies Inc (Salix Pharmaceuticals): Overview

Table 41&nbsp;&nbsp; Bausch Health Companies Inc (Salix Pharmaceuticals): Product Portfolio

Table 42&nbsp;&nbsp; Bausch Health Companies Inc (Salix Pharmaceuticals): Key Developments

Table 43&nbsp;&nbsp; Bristol-Myers Squibb Company: Overview

Table 44&nbsp;&nbsp; Bristol-Myers Squibb Company: Product Portfolio

Table 45&nbsp;&nbsp; Bristol-Myers Squibb Company: Key Developments

Table 46&nbsp;&nbsp; Cosmo Pharmaceuticals NV: Overview

Table 47&nbsp;&nbsp; Cosmo Pharmaceuticals NV: Product Portfolio

Table 48&nbsp;&nbsp; Cosmo Pharmaceuticals NV: Key Developments

Table 49&nbsp;&nbsp; Immuron Limited: Overview

Table 50&nbsp;&nbsp; Immuron Limited: Product Portfolio

Table 51&nbsp;&nbsp; Immuron Limited: Key Developments

Table 52&nbsp;&nbsp; Johnson &amp; Johnson: Overview

Table 53&nbsp;&nbsp; Johnson &amp; Johnson: Product Portfolio

Table 54&nbsp;&nbsp; Johnson &amp; Johnson: Key Developments

Table 55&nbsp;&nbsp; Pfizer: Overview

Table 56&nbsp;&nbsp; Pfizer: Product Portfolio

Table 57&nbsp;&nbsp; Pfizer: Key Developments

Table 58&nbsp;&nbsp; Procter &amp; Gamble: Overview

Table 59&nbsp;&nbsp; Procter &amp; Gamble: Product Portfolio

Table 60&nbsp;&nbsp; Procter &amp; Gamble: Key Developments

Table 61&nbsp;&nbsp; Sanofi S.A: Overview

Table 62&nbsp;&nbsp; Sanofi S.A: Product Portfolio

Table 63&nbsp;&nbsp; Sanofi S.A: Key Developments

Table 64&nbsp;&nbsp; Valneva Canada Inc: Overview

Table 65&nbsp;&nbsp; Valneva Canada Inc: Product Portfolio

Table 66&nbsp;&nbsp; Valneva Canada Inc: Key Developments

Table 67&nbsp;&nbsp; Sun Pharmaceutical Industries Ltd: Overview

Table 68&nbsp;&nbsp; Sun Pharmaceutical Industries Ltd: Product Portfolio

Table 69&nbsp;&nbsp; Sun Pharmaceutical Industries Ltd: Key Developments

List of Figures

Figure 1&nbsp;&nbsp;&nbsp; Global Traveler&#39;s Diarrhea Market Share, By Drug Class, 2021 &amp; 2029(%)

Figure 2&nbsp;&nbsp; Global Traveler&#39;s Diarrhea Market Share, By Pathogen, 2021 &amp; 2029(%)

Figure 3&nbsp;&nbsp; Global Traveler&#39;s Diarrhea Market Share, By Age Group, 2021 &amp; 2029(%)

Figure 4&nbsp;&nbsp; Global Traveler&#39;s Diarrhea Market Share, By Distribution Channel, 2021 &amp; 2029(%)

Figure 5&nbsp;&nbsp; Global Traveler&#39;s Diarrhea Market Share, By Region, 2021 &amp; 2029(%)

Figure 6&nbsp;&nbsp; Global Traveler&#39;s Diarrhea Market Value, 2018-2029($ Million)

Figure 7&nbsp;&nbsp;&nbsp; Global Traveler&#39;s Diarrhea Market Y-o-Y Growth, By Drug Class, 2021 &amp; 2029(%)

Figure 8&nbsp;&nbsp; Antibiotics: Global Traveler&#39;s Diarrhea Market Value, 2018-2029($ Million)

Figure 9&nbsp;&nbsp; Oral Rehydration Therapy (ORS): Global Traveler&#39;s Diarrhea Market Value, 2018-2029($ Million)

Figure 10 Antidiarrheal Agents: Global Traveler&#39;s Diarrhea Market Value, 2018-2029($ Million)

Figure 11&nbsp; Vaccines/Prophylactics: Global Traveler&#39;s Diarrhea Market Value, 2018-2029($ Million)

Figure 12 Others: Global Traveler&#39;s Diarrhea Market Value, 2018-2029($ Million)

Figure 13 Global Traveler&#39;s Diarrhea Market Y-o-Y Growth, By Pathogen, 2021 &amp; 2029(%)

Figure 14 Bacteria: Global Traveler&#39;s Diarrhea Market Value, 2018-2029($ Million)

Figure 15 Viruses: Global Traveler&#39;s Diarrhea Market Value, 2018-2029($ Million)

Figure 16 Protozoa: Global Traveler&#39;s Diarrhea Market Value, 2018-2029($ Million)

Figure 17&nbsp; Global Traveler&#39;s Diarrhea Market Y-o-Y Growth, By Age Group, 2021 &amp; 2029(%)

Figure 18 Adults: Global Traveler&#39;s Diarrhea Market Value, 2018-2029($ Million)

Figure 19 Children: Global Traveler&#39;s Diarrhea Market Value, 2018-2029($ Million)

Figure 20 Global Traveler&#39;s Diarrhea Market Y-o-Y Growth, By Distribution Channel, 2021 &amp; 2029(%)

Figure 21 Hospital Pharmacies: Global Traveler&#39;s Diarrhea Market Value, 2018-2029($ Million)

Figure 22 Retail Pharmacies: Global Traveler&#39;s Diarrhea Market Value, 2018-2029($ Million)

Figure 23 Online Pharmacies: Global Traveler&#39;s Diarrhea Market Value, 2018-2029($ Million)

Figure 24 Global Traveler&#39;s Diarrhea Market Y-o-Y Growth, By Region, 2021 &amp; 2029(%)

Figure 25 North America Traveler&#39;s Diarrhea Market Value, 2018-2029($ Million)

Figure 26 North America Traveler&#39;s Diarrhea Market Share, By Drug Class, 2021 &amp; 2029(%)

Figure 27 North America Traveler&#39;s Diarrhea Market Share, By Pathogen, 2021 &amp; 2029(%)

Figure 28 North America Traveler&#39;s Diarrhea Market Share, By Age Group, 2021 &amp; 2029(%)

Figure 29 North America Traveler&#39;s Diarrhea Market Share, By Distribution Channel, 2021 &amp; 2029(%)

Figure 30 North America Traveler&#39;s Diarrhea Market Share, By Country, 2021 &amp; 2029(%)

Figure 31 South America Traveler&#39;s Diarrhea Market Value, 2018-2029($ Million)

Figure 32 South America Traveler&#39;s Diarrhea Market Share, By Drug Class, 2021 &amp; 2029(%)

Figure 33 South America Traveler&#39;s Diarrhea Market Share, By Pathogen, 2021 &amp; 2029(%)

Figure 34 South America Traveler&#39;s Diarrhea Market Share, By Age Group, 2021 &amp; 2029(%)

Figure 35 South America Traveler&#39;s Diarrhea Market Share, By Distribution Channel, 2021 &amp; 2029(%)

Figure 36 South America Traveler&#39;s Diarrhea Market Share, By Country, 2021 &amp; 2029(%)

Figure 37 Europe Traveler&#39;s Diarrhea Market Value, 2018-2029($ Million)

Figure 38 Europe Traveler&#39;s Diarrhea Market Share, By Drug Class, 2021 &amp; 2029(%)

Figure 39 Europe Traveler&#39;s Diarrhea Market Share, By Pathogen, 2021 &amp; 2029(%)

Figure 40 Europe Traveler&#39;s Diarrhea Market Share, By Age Group, 2021 &amp; 2029(%)

Figure 41 Europe Traveler&#39;s Diarrhea Market Share, By Distribution Channel, 2021 &amp; 2029(%)

Figure 42 Europe Traveler&#39;s Diarrhea Market Share, By Country, 2021 &amp; 2029(%)

Figure 43 Asia-Pacific Traveler&#39;s Diarrhea Market Value, 2018-2029($ Million)

Figure 44 Asia-Pacific Traveler&#39;s Diarrhea Market Share, By Drug Class, 2021 &amp; 2029(%)

Figure 45 Asia-Pacific Traveler&#39;s Diarrhea Market Share, By Pathogen, 2021 &amp; 2029(%)

Figure 46 Asia-Pacific Traveler&#39;s Diarrhea Market Share, By Age Group, 2021 &amp; 2029(%)

Figure 47 Asia-Pacific Traveler&#39;s Diarrhea Market Share, By Distribution Channel, 2021 &amp; 2029(%)

Figure 48 Asia-Pacific Traveler&#39;s Diarrhea Market Share, By Country, 2021 &amp; 2029(%)

Figure 49 Middle East &amp; Africa Traveler&#39;s Diarrhea Market Value, 2018-2029($ Million)

Figure 50 Middle East &amp; Africa Traveler&#39;s Diarrhea Market Share, By Drug Class, 2021 &amp; 2029(%)

Figure 51 Middle East &amp; Africa Traveler&#39;s Diarrhea Market Share, By Pathogen, 2021 &amp; 2029(%)

Figure 52 Middle East &amp; Africa Traveler&#39;s Diarrhea Market Share, By Age Group, 2021 &amp; 2029(%)

Figure 53 Middle East &amp; Africa Traveler&#39;s Diarrhea Market Share, By Distribution Channel, 2021 &amp; 2029(%)

Figure 54 Bausch Health Companies Inc (Salix Pharmaceuticals): Financials

Figure 55 Bristol-Myers Squibb Company: Financials

Figure 56 Cosmo Pharmaceuticals NV: Financials

Figure 57 Immuron Limited: Financials

Figure 58 Johnson &amp; Johnson: Financials

Figure 59 Pfizer: Financials

Figure 60 Procter &amp; Gamble: Financials

Figure 61 Sanofi S.A: Financials

Figure 62 Valneva Canada Inc: Financials

Figure 63 Sun Pharmaceutical Industries Ltd: Financials